Capital International Ltd. CA cut its holdings in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 17.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 53,756 shares of the life sciences company’s stock after selling 11,093 shares during the quarter. Capital International Ltd. CA’s holdings in Illumina were worth $7,051,000 as of its most recent filing with the SEC.
Other institutional investors also recently bought and sold shares of the company. Elyxium Wealth LLC acquired a new position in Illumina in the fourth quarter valued at $25,000. Board of the Pension Protection Fund acquired a new position in Illumina in the fourth quarter valued at $26,000. Creative Capital Management Investments LLC increased its stake in Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares during the period. TD Waterhouse Canada Inc. acquired a new position in Illumina in the fourth quarter valued at $26,000. Finally, Laurel Wealth Advisors LLC acquired a new position in Illumina in the fourth quarter valued at $26,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research analysts have commented on the stock. Royal Bank Of Canada started coverage on shares of Illumina in a research note on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price objective on the stock. Wall Street Zen lowered shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Piper Sandler dropped their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research note on Monday, February 9th. Canaccord Genuity Group dropped their price target on shares of Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research note on Friday, May 1st. Finally, Evercore reiterated an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Seven investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $138.38.
Insider Activity at Illumina
In related news, CAO Scott D. Ericksen sold 500 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $160.00, for a total transaction of $80,000.00. Following the sale, the chief accounting officer owned 14,446 shares of the company’s stock, valued at approximately $2,311,360. The trade was a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the sale, the director directly owned 2,830,452 shares in the company, valued at approximately $463,146,860.76. This represents a 7.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 1,002,371 shares of company stock worth $155,472,900 in the last ninety days. Corporate insiders own 2.90% of the company’s stock.
Illumina Trading Down 3.4%
Shares of Illumina stock opened at $162.32 on Friday. Illumina, Inc. has a 52-week low of $82.44 and a 52-week high of $177.22. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The company’s 50-day simple moving average is $137.75 and its 200-day simple moving average is $133.57. The firm has a market cap of $24.56 billion, a price-to-earnings ratio of 29.51, a price-to-earnings-growth ratio of 3.04 and a beta of 1.50.
Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm’s revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities research analysts anticipate that Illumina, Inc. will post 5.2 earnings per share for the current year.
About Illumina
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Read More
- Five stocks we like better than Illumina
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
